Purchase Order 36C26024P0566
Award Date
4/30/24
Potential Completion Date
7/30/24
Potential Value
$38K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Accredo Health Group, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bartlett, TN 38134, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $40,697.68 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the supply of specialty pharmaceutical products, including medications to treat pulmonary arterial hypertension, neuropathic lysosomal storage disorders, and ophthalmic disorders. The contract has an ultimate completion date of March 14, 2025 and is part of the VA's Veterans...
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the supply of LUMRYZ (sodium oxybate) 6 GM/PKT, a specialty pharmaceutical product, to the VA's Veterans Integrated Service Network 9. The contract has a ceiling value of $12,222.02 and a period of performance ending on June 30, 2025. The contract was awarded on June 4, 2025, and does not have...
This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs' Veterans Integrated Service Network 22 (VISN 22) to Accredo Health Group, Inc., a for-profit pharmaceutical distributor. The contract, valued at $76,986.72, is for the delivery of the specialty medication "EMERGENCY LUMRYZ 9GM" with a period of performance ending on September 30, 2025. Accredo Health Group, Inc. is a subsidiary of Express Scripts and a key provider of complex and high-value...
This is a $103,003.20 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The contract is for the delivery of various complex and high-value medications, primarily to support the VA's Veterans Integrated Service Network (VISN) healthcare facilities. Key medications provided under this contract include drugs used to treat...
The Department of Veterans Affairs (VA) awarded a firm fixed-price purchase order contract to Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The $10,708.63 contract is for the emergency purchase of sodium oxybate, a medication used to treat certain medical conditions. The contract has a completion date of March 28, 2025 and is part of the VA's Veterans Integrated Service Network 12 (VISN 12) program, which...
This firm fixed-price purchase order, valued at $8,906.37, was awarded by the National Institutes of Health (NIH) Clinical Center to Accredo Health Group, Inc., a specialty pharmacy services provider. The contract is for the delivery of specific medications, such as Uptravi, Tyvaso, and Oxervate, to support treatment programs for the Veterans Health Administration (VHA). Accredo is a subsidiary of Express Scripts and has an established role as a key pharmaceutical distributor in the VA's...
This is a federal contract award to Accredo Health Group, Inc., a prime contractor, by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 5. The contract is for the "RATIFICATION OF UNAUTHORIZED COMMITMENT" and "MEDICAL PRESCRIPTION" services, with a potential value of $130,050.45. The contract is a Firm Fixed Price Purchase Order with no set-aside designation, and the period of performance runs through March 31,...
This is a federal contract award to Accredo Health Group, Inc., a prime contractor, by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 21. The award is for the specialty medication UPTRAVI, with a potential value of $104,778.03 and a completion date of September 30, 2021. The contract is a firm fixed price purchase order with no set-aside designation. Accredo Health Group, a for-profit organization, provides specialty pharmacy...
This is a $81,632.25 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit subsidiary of Express Scripts that specializes in providing specialty pharmaceutical services. The contract is for the delivery of the medication Tyvaso, which is used to treat pulmonary arterial hypertension. The contract has no set-aside designation and was awarded on April 6, 2021, with a completion date of September 30, 2021....
The U.S. Department of Veterans Affairs (VA) awarded a $81,342.18 firm fixed-price purchase order contract to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, to provide the specialty pharmaceutical TYVASO. The contract, which does not have a set-aside designation, is to support the VA's Veterans Integrated Service Network 21 (VISN 21) and has an ultimate completion date of September 30, 2022. Accredo Health Group, Inc. is a key distributor of complex and...